Fig. 3From: Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N’Djamena, Chad: findings from a cross-sectional studyPrevalence of NNRTI DRMs. NNRTI non-nucleoside reverse transcriptase inhibitors, DRMs drug resistant mutationsBack to article page